EUVIMEDEUVIMED entdecken
Crossref

High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma

Hirokazu Kobushi, Satoshi Saida iD, Katsutsugu Umeda iD, Atsushi Iwai, Kagehiro Kozuki, Hirohito Kubota iD, Kuniaki Tanaka, Satoshi Obu, Yoshinori Uchihara, Keiji Tasaka iD, Itaru Kato iD, Hidefumi Hiramatsu und 1 weitere

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Hirokazu Kobushi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Neuroblastoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is no clear consensus on the most effective treatment for relapsed/refractory high‐risk neuroblastoma (NB). We retrospectively assessed seven NB patients with relapsed/refractory disease who received high‐dose carboplatin–irinotecan–temozolomide (HD‐CIT). Five of seven patients showed favorable therapeutic response (complete remission or partial remission). Regarding toxicity, the cytopenia period tended to prolong when more than three cycles were repeated, but nonhematological toxicities were controllable with general supportive care. Due to its antitumor efficacy and well‐tolerated nonhematologic toxicity, HD‐CIT is a promising salvage chemotherapy for relapsed/refractory NB. However, it is important to pay attention to the exacerbation of hematological toxicity when repeating the regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaHumansCarboplatinIrinotecanTemozolomideRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsSalvage TherapyNeoplasm Recurrence, Local

Stichwörter der Autor:innen

HD-CIThigh-risk neuroblastomairinotecanrefractoryrelapsedsalvage chemotherapytemozolomide

Substanzen

CarboplatinIrinotecanTemozolomide

Autor:innen und Institutionen

  • Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

ORCID-Profile: Satoshi Saida, Katsutsugu Umeda, Hirohito Kubota, Keiji Tasaka, Itaru Kato

Zitieren

APA

Kobushi, H., Saida, S., Umeda, K., Iwai, A., Kozuki, K., Kubota, H., Tanaka, K., Obu, S., Uchihara, Y., Tasaka, K., Kato, I., Hiramatsu, H., & Takita, J. (2023). High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30331

Vancouver

Kobushi H, Saida S, Umeda K, Iwai A, Kozuki K, Kubota H, et al. High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30331

BibTeX
@article{Kobushi2023,
  author = {Kobushi, Hirokazu and Saida, Satoshi and Umeda, Katsutsugu and Iwai, Atsushi and Kozuki, Kagehiro and Kubota, Hirohito and Tanaka, Kuniaki and Obu, Satoshi and Uchihara, Yoshinori and Tasaka, Keiji and Kato, Itaru and Hiramatsu, Hidefumi and Takita, Junko},
  title = {High‐dose carboplatin–irinotecan–temozolomide is an effective salvage chemotherapy for relapsed or refractory neuroblastoma},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30331}
}
Kostenlos starten →